LQDA

54.5103.74%
AS

Arthur S. Kirsch

Independent Director

Mr. Arthur S. Kirsch, M.B.A., is Independent Director of Evommune, Inc. from November 2025. He is Director of Atea Pharmaceuticals, Inc. from February 24, 2025. Mr. Kirsch is a Senior Advisor with Alvarez and Marsal within the Life Sciences sector. He is Director at Anavasi Diagnostics. Previously, Mr. Kirsch was a Senior Advisor and Head of Healthcare at GCA Global LLC from June 2005 to 2019. Mr. Kirsch served as Managing Director and Global Head of Medical Devices and Diagnostics at GCA Corporation (formerly known as GCA Savvian Corporation). From May 2004 until February 2016, Mr. Kirsch served as a director of POZEN Inc. Mr. Kirsch served has been an Independent Director at Kadmon Holdings Inc. since 2019. Mr. Kirsch serves on the Board of Directors of Liquidia Technologies, Inc. He previously served on the Board of Kadmon Holdings, Inc. He was a Senior Advisor with the investment bank, GCA, LLC (formerly, GCA Savvian, LLC (formerly Perseus Group, LLC)) since June 2005. He is business and financial expertise and experience serving on the boards of directors of several public pharmaceutical and life sciences companies. He has experience in working in the equity capital markets and has extensive knowledge of the healthcare and life sciences field. Mr. Kirsch has spent the majority of his career in investment banking with a focus on the healthcare industry. Over the time, he has completed numerous public and private financings along with a wide range of strategic advisory assignments. His clients have included Sonosite, Thoratec, OSI Pharmaceuticals, Olympus, Nihon Kohden and Thermo Electron. He served as Senior Vice President and Director of International Equity at Vector Securities International, LLC. from 1995 to 1999. Mr. Kirsch was the Director of Equity Research of Vector Securities International, Inc. from 1995 to 1999. He was a Founding Member and Managing Director at Vector Securities LLC from 2001 to May 2005. He served as a Managing Director with Savvian LLC, focusing on the Healthcare sector. From May 1994 to May 2004, he served as executive vice president, head of research at Vector Securities, LLC, a brokerage firm. From June 1979 to February 1990, Mr. Kirsch began his career on Wall Street at Drexel Burnham Lambert, Inc., an investment banking firm, where he held the position of executive vice president and head of equity division (Director of the Global Equity Division). He was a Managing Director and Head of Healthcare Research and Capital Markets at Prudential Vector Healthcare Group, a unit of Prudential Securities, Inc., a full-service brokerage firm, from 1999 to 2001. He served senior leadership positions at Prudential Vector Healthcare Group, a unit of Prudential Securities Inc. and at Vector Securities International Inc. Before joining Vector in 1995, he served as the President and Chief Executive Officer of NatWest Securities U.S. From February 1990 to May 1993, Mr. Kirsch served as president of Natwest Securities Limited, a brokerage firm. He served as the Chairperson of Aralez Pharmaceuticals Inc. since February 5, 2016 until May 2019 and served as its Director from February 5, 2016 to May 2019. He served as director of Kadmon Corporation (NYSE: KDMN) since May 2019 until November 2021. He has been an Independent Director of Liquidia Corporation since September 2016. He serves as a Director of PhysioSonics, Inc. He served as a Director of Immunomedics Inc. from August 2015 to October 13, 2016. Mr. Kirsch is a consultant. Mr. Kirsch received his BS and BA in Finance from the University of Rhode Island and his MBA degree in Finance from Bernard M. Baruch College.

Positions